亨廷顿病临床试验角落:2023年8月
Carlos Estevez-Fraga1, Sarah J Tabrizi1, Edward J Wild1
1Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, UK.
Journal of Huntington's disease
|July 24, 2023
概括
本更新涵盖正在进行的亨廷顿病临床试验,包括GENERATION HD2 (tominersen),AB-1001和PROOF-HD的发现. 它提供了针对亨廷顿病研究的当前和注册试验的全面列表.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 临床研究 临床研究
背景情况:
- 亨廷顿病 (HD) 是一种进展性神经退行性疾病.
- 对于HD有效的治疗干预措施有极大需要.
- 临床试验对于推进疾病治疗策略至关重要.
研究的目的:
- 提供有关亨廷顿病关键正在进行的临床试验的最新信息.
- 讨论特定的试验,如GENERATION HD2 (tominersen) 和阿斯克莱皮斯生物制药/BrainVectis试验 (AB-1001).
- 审查PROOF-HD试验的最新发现,并编制所有已注册和正在进行的HD临床试验的综合清单.
主要方法:
- 审查正在进行的临床试验数据和最近的出版物.
- 包括来自相关数据库的注册试验信息.
- 专家对试验进展和结果的评论.
主要成果:
- 更新详细介绍了GENERATION HD2和AB-1001试验的状态和范围.
- 讨论了PROOF-HD试验的最新发现.
- 这里列出了目前注册和正在进行的亨廷顿病临床试验的综合清单.
结论:
- 亨廷顿病临床研究的景观是活跃和不断发展的.
- 持续监测这些试验对于了解治疗潜力至关重要.
- 这一概述是研究人员,临床医生和患者的宝贵资源.
相关概念视频
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
Parkinson's Disease: Treatment
301
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
301
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Parkinson's Disease: Overview
601
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
601
Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525


